Can a graduate of the Harvard Kennedy School hold on to free market principles? Accad and Koka discuss health policy and economics with neurosurgeon Dr. Richard Menger.
Big Pharma is abandoning its R&D efforts for antibiotics. What are the regulatory, scientific, and economic factors responsible for this potentially dangerous trend? Accad and Koka interview Dr. David Shlaes.
In Canada, it is estimated that between 25,456 and 63,090 Canadian women may have died as a result of increased wait times between 1993 and 2009.
Here we see two rival strategies to marketing healthcare services. The status quo is based on insurance payments and price secrecy. Walmart's strategy is based on price competition.
Jay Kempton shares insights from his recent efforts to turn employers away from the wasteful and corrupt health insurance benefit model.
Bob Graboyes on why American healthcare is stuck in a hundred-year-old mentality that stifles innovation, constrains medical advances, and yields low quality care.
Dr. Keith Smith offers insights into the chasm that exists between the way healthcare policy makers conceive of medical practice and how ordinary patients actually seek the best possible healthcare value.
Dr. Joel Topf shares his insights on the good and bad of Trump's executive order, and on the state and future of kidney disease in the United States.
Bob Murphy and Michel Accad discuss Kenneth Arrow's pioneering 1963 article on healthcare economics.
